Imreplys
What Imreplys is used for
Imreplys is indicated for treatment of patients of all ages acutely exposed to myelosuppressive doses of radiation with Haematopoietic Sub-syndrome of Acute Radiation Syndrome (H-ARS). Imreplys should be used in accordance with official radiological/nuclear emergency recommendations.
Approved use, as published by the European Medicines Agency.
What the labels mean
- Approved under exceptional circumstances: full data cannot be collected, usually because the disease is very rare.
Key facts
- Brand
- Imreplys
- Active substance
- sargramostim
- Disease area
- Acute Radiation Syndrome
- Medicine group
- Immunostimulants
- ATC code
- L03AA09
- Marketing authorisation holder
- Partner Therapeutics Limited
- Authorised in the EU since
- 2025
Official information
In the USA
Same active substance: Leukine
In India
- Sargramostim: 2 brands in India
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Imreplys used for?
Imreplys is indicated for treatment of patients of all ages acutely exposed to myelosuppressive doses of radiation with Haematopoietic Sub-syndrome of Acute Radiation Syndrome (H-ARS). Imreplys should be used in accordance with official radiological/nuclear emergency recommendations.
What is the active substance in Imreplys?
Imreplys contains sargramostim.
Who makes Imreplys?
The EU marketing authorisation holder is Partner Therapeutics Limited.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU